• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Saturday 09/22/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

ENDV

  • 12:13 PM

    LOS ANGELES, CA, Jan. 11, 2018 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a clinical-stage developer of non-invasive electroceuticals for the treatment of central nervous system (CNS) disorders, today announced it is working with ShareIntel – Shareholder Intelligence Services to continue its commitment to protecting its shareholders and maximizing shareholder value. ShareIntel offers unprecedented access and insight into broker-dealer, clearing firm and shareholder position movement. ShareIntel utilizes a patented process called DRIL-DownTM to aggregate and analyze historic repository data

    Read more
  • 6:56 PM

    Financing to be Used for the Development of a Portfolio of Treatments for Vascular Diseases and Ischemic Injuries Using Endonovo’s Immunotronics Platform LOS ANGELES, CA–ENDV, (Marketwired – Nov 28, 2016) – Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a developer of non-invasive electroceuticals for the treatment of inflammatory conditions and diseases in vital organs, today announced that it has signed a term sheet with a single strategic healthcare investor for $5 million in Series B Preferred Stock financing

    Read more
  • 2:25 PM

    Key Patent Covers Production of Human Proteins Used as Biologics, including EPO, G-CSF, GM-CSF, and IL-2 LOS ANGELES, CA– ENDV, (Marketwired – Aug 9, 2016) – Endonovo Therapeutics, Inc. (OTCQB: ENDV), a developer of bioelectronic devices and non-invasive Electroceuticals for the treatment of inflammatory conditions in vital organs, announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,410,143 covering the use of electromagnetic stimulation of cells to produce biological molecules. This newly-issued patent covers the production

    Read more
  • 3:14 PM

    Acquisition of RGN’s Electroceutical(TM) Product Portfolio and Intellectual Property LOS ANGELES, CA– ENDV, (Marketwired – Jul 11, 2016) – Endonovo Therapeutics, Inc. (OTCQB: ENDV) — a developer of bioelectronic devices and medicines, announced today it has executed a binding letter of intent (LOI) to acquire Rio Grande Neurosciences, Inc. (RGN), a privately-held clinical stage developer of non-invasive Electroceuticals™ for the treatment of neuro-inflammation and central nervous system diseases and disorders. The LOI is binding, but subject to the execution of

    Read more
  • 2:48 PM

    SAN ANTONIO, TX–(Marketwired – Jun 13, 2014) – EnerJex Resources, Inc. (OTCQB: ENRJD) (OTCQB: ENRJ) (“EnerJex” or the “Company”) announced today that it has received authorization to list its common stock and its proposed 10% Series A Perpetual Preferred Stock on the NYSE MKT. The Company presently anticipates that trading of these securities on the NYSE MKT may commence on June 17, 2014. EnerJex’s common stock will trade under the symbol “ENRJ,” and its preferred stock will trade under the symbol “ENRJPR”.

    Read more
Public Wire Banner